Cardiac Stem Cell Alliances Include Large Firms; MacroPore “Grows” It Alone
This article was originally published in The Gray Sheet
Executive Summary
MacroPore Biosurgery insists it will pursue solo development of stem cell therapy for myocardial infarction, even though competitors are increasingly aligning with large cardiovascular device firms